Adrian Quartel was named Chief Medical Officer of Spruce Biosciences, Inc. As of November 6, 2026, Spruce Biosciences, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on July 27, 2026, naming 1 appointment (Form 8-K, July 27, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Spruce Biosciences, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Spruce Biosciences, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-07-27. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Spruce Biosciences, Inc. files it.
Also on the record for Spruce Biosciences, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 14, 2026 | Stake report, Schedule 13G, by AWM Investment Company, Inc. | 5.1% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G, by OrbiMed Advisors LLC | 4.8% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by ADAR1 Capital Management, LLC | 2.5% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by Kenneth Griffin | 1.9% of the class | 5%+ stakes | Source |
| August 4, 2026 | Stake report, Schedule 13G/A, by Integrated Core Strategies (US) LLC | 5.8% of the class | 5%+ stakes | Source |
| July 30, 2026 | Stake report, Schedule 13G, by BlackRock, Inc. | 6.8% of the class | 5%+ stakes | Source |
| July 27, 2026 | Stake report, Schedule 13G, by Orin Hirschman | 9.1% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by Alyeska Investment Group, L.P. | 4.49% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by Citadel Advisors LLC | 5.1% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by Squadron Master Fund LP | 0.9% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by Wellington Management Group LLP | 3.6% of the class | 5%+ stakes | Source |
| May 7, 2026 | Stake report, Schedule 13G/A, by Ikarian Capital, LLC | 4.8% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Spruce Biosciences, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Spruce Biosciences, Inc. and the records around it.
Spruce Biosciences, Inc. elsewhere on the record
- 5%+ stake filings Aug 2026
- Form D filing Oct 2025
- Who owns it
Companies that share a holder
- Rock Springs Capital Management LP also filed stake reports on 1 other company: TALPHERA, INC. (Sep 2025)
- ExodusPoint Capital Management, LP also filed stake reports on 3 other companies: RE/MAX Holdings, Inc. (Aug 2026), Keros Therapeutics, Inc. (Feb 2026), ALT5 Sigma Corp (Aug 2025)
- The Carlyle Group Inc. also filed stake reports on 7 other companies: SunPower Inc. (Aug 2026), Q32 Bio Inc. (Jul 2026), Medline Inc. (May 2026)
Watch Spruce Biosciences, Inc.
Get an email when Spruce Biosciences, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Spruce Biosciences, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Spruce Biosciences, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Spruce Biosciences, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
13 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 29 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-07-27 | In | Chief Medical Officer | 8-K, 2026-07-27 |
Who leads Spruce Biosciences, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Medical Officer: Adrian Quartel, appointed (filed 2026-07-27).
New leaders reset buying decisions — get the Full Report on Spruce Biosciences, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Medical Officer at Spruce Biosciences, Inc., with the record behind each one.
Find candidates like Chief Medical Officer at Spruce Biosciences, Inc.Every change, in the filing's words
Appointed: Adrian Quartel, Chief Medical Officer
On July 27, 2026, Spruce Biosciences, Inc. (the "Company") appointed Adrian Quartel, M.D., FFPM, as the Company's Chief Medical Officer, replacing Dr. Kirk Ways, who had been serving as the Company's Interim Chief Medical Officer.
- Dr. Ways will continue to serve as a member of the Company's Board of Directors.
- Dr. Quartel brings more than 25 years of experience in the international pharmaceutical industry, with senior roles spanning clinical development, pharmacovigilance, and medical affairs, and a track record of advancing and launching enzyme replacement therapies for rare diseases.
- Dr. Quartel most recently served as Chief Medical Officer of Zevra Therapeutics, where he helped guide the clinical development, medical affairs, and regulatory strategy for the company's rare disease portfolio.
- Prior to Zevra, he served as Chief Medical Officer of Acer Therapeutics and Chief Medical Officer of Adamas Pharmaceuticals, a company focused on drug development for neurological diseases.
- Earlier, as Group Vice President of Global Medical Affairs at BioMarin Pharmaceutical, Dr. Quartel spearheaded the launch of six treatments for rare diseases and genetic disorders, including the enzyme replacement therapies NAGLAZYME, VIMIZIM, and Brineura.
- Before BioMarin, Dr. Quartel oversaw clinical development and held senior medical leadership positions at Astellas, Chiltern, and ICON Clinical Research.
Tools for this story
Each opens in a new tab, filled in for Spruce Biosciences, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.